Haemophilus influenzae Infections

Organism/Misnomer

Small pleomorphic Gram-negative coccobacillus. Name = HISTORICAL MISNOMER — isolated during 1889-92 flu pandemic, wrongly presumed cause (true viral cause found decades later, name stuck).

“Haemophilus” = needs Factor X (hemin/hematin) + Factor V (NAD). Chocolate agar (lysed blood, releases both) YES. Blood agar (intact RBC) NO — unless SATELLITE PHENOMENON (grows near S. aureus streak, staph hemolysis releases factors, see General Microbiology topic).

Capsular Typing — Central Distinction

Encapsulated (6 serotypes a-f) vs Non-encapsulated (non-typeable, NTHi).

Type b (Hib): historically DOMINANT cause of SEVERE INVASIVE disease (meningitis, epiglottitis, bacteremia) in unvaccinated — antiphagocytic capsule (same logic as pneumococcus). NTHi: less invasive, but IMPORTANT cause of MUCOSAL non-invasive disease (otitis media, sinusitis, COPD exacerbations) — Hib vaccine gives NO protection here.

Clinical Manifestations

Invasive Hib (unvaccinated children, historically dominant):

Meningitis — leading pediatric bacterial meningitis cause pre-vaccine (CNS topic)
EPIGLOTTITIS — AIRWAY EMERGENCY. Acute rapid supraglottic swelling → complete obstruction risk. High fever, drooling, stridor, TRIPOD POSITION. Urgent controlled airway mgmt, AVOID aggressive throat exam (can precipitate obstruction)
Bacteremia, septic arthritis, cellulitis (periorbital/facial, young children)

NTHi: otitis media + sinusitis (with pneumococcus = 2 dominant bacterial causes, see Ocular/Ear topic). COPD exacerbations (exploits compromised mucociliary clearance).

Laboratory Diagnosis

Culture: CHOCOLATE AGAR specifically (or blood agar + staph streak = satellitism, presumptive alternative). Factor X/V requirement testing distinguishes from related species (e.g. H. parainfluenzae = factor V only, see IE/HACEK topic). Gram stain: small pleomorphic Gram-negative coccobacilli, sterile site (CSF) — rapid presumptive. Capsular serotyping (slide agglutination/PCR): distinguishes type b from other types/NTHi, clinical + surveillance use.

Treatment

3rd-gen cephalosporin (ceftriaxone/cefotaxime) = standard serious invasive disease — ↑BETA-LACTAMASE ampicillin resistance in many strains (shift away from ampicillin empirical use, see AMR topic). Epiglottitis: urgent controlled airway management (OR setting, anesthesia/ENT standby) PRIORITY alongside antibiotics.

Prevention — Hib Vaccine

Hib CONJUGATE vaccine (polysaccharide+carrier protein, T-independent→T-dependent conversion, same logic as PCV, see Vaccines topic). DRAMATIC impact — >90% ↓invasive Hib disease with good coverage. India NIS: pentavalent vaccine, 6/10/14 weeks (see Vaccines topic).

LIMITATION: protects ONLY type b — NOTHING against NTHi or other rarer encapsulated types. NTHi-driven otitis/sinusitis/COPD exacerbations UNAFFECTED by Hib coverage.

The Organism and a Historical Misnomer

Haemophilus influenzae is a small, pleomorphic, Gram-negative coccobacillus, whose species name is a genuine historical misnomer worth explaining directly: it was originally isolated from patients during the devastating 1889–1892 influenza pandemic and mistakenly presumed to be the pandemic’s actual cause — the true cause (influenza virus) was not identified until decades later, by which point the bacterium’s name had already stuck despite having no causal role in influenza at all. The organism’s genus name, Haemophilus (“blood-loving”), reflects its genuinely fastidious growth requirement for two blood-derived factors: factor X (haemin/haematin) and factor V (NAD) — both supplied by chocolate agar (lysed blood, releasing both factors freely) but not by ordinary blood agar (where intact red cells don’t release these factors on their own, unless a helper organism happens to lyse nearby cells) — the same satellite phenomenon covered under General Microbiology, where H. influenzae colonies cluster specifically around a streak of S. aureus on blood agar, since staphylococcal haemolysis releases the factors H. influenzae needs but blood agar alone doesn’t provide.

Capsular Typing and the Central Clinical Distinction

H. influenzae strains split into encapsulated (six serotypes, a–f, based on capsular polysaccharide) and non-encapsulated (non-typeable, NTHi) groups, and this single distinction predicts nearly everything else clinically relevant about a given isolate: capsular type b (Hib) was historically responsible for the overwhelming majority of severe, invasive H. influenzae disease (meningitis, epiglottitis, bacteraemia) in unvaccinated populations, given the capsule’s antiphagocytic function mirroring the same encapsulated-pathogen logic covered under Pneumococcal Pneumonia; non-typeable strains, lacking this capsule, are considerably less invasive but remain a genuinely important cause of mucosal, non-invasive respiratory disease — otitis media, sinusitis, and exacerbations of chronic bronchitis/COPD — in both vaccinated and unvaccinated populations, since the Hib vaccine (below) targets the type b capsule specifically and provides no protection against NTHi at all.

Clinical Manifestations

Invasive Hib disease (in unvaccinated children, historically the dominant cause) included meningitis (a leading cause of bacterial meningitis in young children before vaccination, covered under Central Nervous System Infections), epiglottitis (a genuine airway emergency — acute, rapidly progressive supraglottic inflammation and swelling risking sudden, complete airway obstruction, presenting with high fever, drooling, stridor, and a characteristic tripod sitting position as the child instinctively optimizes airway patency, requiring urgent, carefully managed airway control rather than aggressive throat examination, which can precipitate complete obstruction), bacteraemia, septic arthritis, and cellulitis (classically periorbital/facial in young children). Non-typeable H. influenzae causes otitis media and sinusitis (alongside pneumococcus as the two dominant bacterial causes of both, see Ocular and Ear Infections), and is a significant cause of acute exacerbations in patients with underlying chronic obstructive pulmonary disease, exploiting the already-compromised mucociliary clearance in that population.

Laboratory Diagnosis

Culture requires chocolate agar specifically (or blood agar with a staphylococcal streak to demonstrate satellitism, as a presumptive alternative when chocolate agar isn’t available), given the factor X/V requirement described above; growth factor requirement testing (does the isolate need X alone, V alone, or both) helps distinguish H. influenzae from related Haemophilus species with different factor requirements (e.g. H. parainfluenzae, which needs only factor V, covered under Infective Endocarditis’s HACEK discussion). Gram stain of CSF or another sterile site specimen showing small, pleomorphic Gram-negative coccobacilli supports rapid presumptive diagnosis in invasive disease. Capsular serotyping (by slide agglutination or PCR) distinguishes type b from other encapsulated types and from non-typeable strains, relevant for both clinical management and public health surveillance of vaccine impact.

Treatment

Third-generation cephalosporins (ceftriaxone or cefotaxime) are standard for serious invasive disease (meningitis, epiglottitis), given increasing beta-lactamase-mediated ampicillin resistance in many circulating strains (a real, practical shift away from ampicillin as reliable empirical first-line therapy, mirroring the beta-lactamase resistance mechanism covered under Antimicrobial Agents and Antimicrobial Resistance). Epiglottitis specifically requires urgent, controlled airway management (often in an operating room setting with anaesthesia/ENT support standing by) as an immediate priority alongside antibiotics, given the airway-obstruction risk described above.

Prevention: Hib Vaccination

The Hib conjugate vaccine — capsular polysaccharide conjugated to a carrier protein, converting the response from T-independent to T-dependent (the same conjugation logic covered under Vaccines and Immunoprophylaxis and mirrored by pneumococcal conjugate vaccine) — has had a genuinely dramatic public health impact, reducing invasive Hib disease by over 90% in populations with good coverage, to the point that Hib meningitis and epiglottitis, once among the commonest causes of severe childhood bacterial disease, are now rare in well-vaccinated populations. It is part of the pentavalent vaccine given in India’s National Immunization Schedule (see Vaccines and Immunoprophylaxis) at 6, 10, and 14 weeks. The vaccine’s genuinely important limitation, worth restating precisely: it protects only against type b, doing nothing against non-typeable strains or the other, far less common encapsulated serotypes — so NTHi-driven otitis media, sinusitis, and COPD exacerbations remain entirely unaffected by Hib vaccination coverage.